Annual report
7129.TEDINET S100TX1I
Period2023-04-01 → 2024-03-31
Filed2024-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 99
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥22.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥22.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥19.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥395m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥191m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥374m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥169m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥190m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥64m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥348m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥6m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥210m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥292m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥6m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥210m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥13.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥14.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥14.2bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.5bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥10.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2022-03-31d | Cons. | Net assets |
| Cash and deposits | ¥1.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.3bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥919m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥336m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥557m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥610m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥369m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥2.21 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥84.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥117.49 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥2.2 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.84 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥116.61 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,307.63 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,341.2 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,287.13 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 23.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.5% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 0.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,741 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,782 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 1,752 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥322m | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥278m | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥116m | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥126m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥85m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥124m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥90m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥52m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥124m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥90m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥94m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥60m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥62m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥3.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥3.2bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥3.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥107m | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥141m | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.1bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.1bn | at 2022-03-31d | Standalone | Net assets |
| Cash and deposits | ¥57m | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥32m | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥37.73 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.16 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.86 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥37.51 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.06 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.68 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥30 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,230.31 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,226.96 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,232.94 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 96.6% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.6% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 97.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.1% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,527,300 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,488,700 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,488,300 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 92
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 18 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥972m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥929m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥146m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥28m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥6m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥36m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥42m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥42m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥730m |
| Medicine Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥124m |
| Medicine Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥92m |
| Medicine Businessreportable segment | employees | at 2024-03-31 | 196 pure |
| Medicine Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥9.3bn |
| Medicine Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.3bn |
| Medicine Businessreportable segment | segment assets | at 2024-03-31 | ¥2.9bn |
| Medicine Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥545m |
| Nursing Care Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥79m |
| Nursing Care Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥42m |
| Nursing Care Businessreportable segment | employees | at 2024-03-31 | 300 pure |
| Nursing Care Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| Nursing Care Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| Nursing Care Businessreportable segment | segment assets | at 2024-03-31 | ¥909m |
| Nursing Care Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥131m |
| Nurturing Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥84m |
| Nurturing Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥418m |
| Nurturing Businessreportable segment | employees | at 2024-03-31 | 1180 pure |
| Nurturing Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥9.2bn |
| Nurturing Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.2bn |
| Nurturing Businessreportable segment | segment assets | at 2024-03-31 | ¥7.0bn |
| Nurturing Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥684m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥287m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥551m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥21.8bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥21.8bn |
| —segment total | segment assets | at 2024-03-31 | ¥10.9bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥289m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥555m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥22.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥22.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥42m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥540,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥974m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥945m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥29m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥180m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥48m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥13m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥43m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥29m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥29m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥778m |
| Medicine Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥103m |
| Medicine Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥88m |
| Medicine Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9.0bn |
| Medicine Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥9.0bn |
| Medicine Businessreportable segment | segment assets | at 2023-03-31 | ¥2.9bn |
| Medicine Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥531m |
| Nursing Care Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8m |
| Nursing Care Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥45m |
| Nursing Care Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | segment assets | at 2023-03-31 | ¥1.1bn |
| Nursing Care Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥147m |
| Nurturing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥515m |
| Nurturing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥400m |
| Nurturing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥8.9bn |
| Nurturing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥8.9bn |
| Nurturing Businessreportable segment | segment assets | at 2023-03-31 | ¥7.8bn |
| Nurturing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥537m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥626m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥533m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥21.3bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥21.3bn |
| —segment total | segment assets | at 2023-03-31 | ¥11.9bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥921m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥626m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥536m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥22.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥22.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥29m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥970m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,312
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from long term loans payable fin cf | Prior1YearDuration | 100000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYearDuration | 400000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -649236000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -641411000 | JPY |
| Redemption of bonds fin cf | Prior1YearDuration | -41000000 | JPY |
| Redemption of bonds fin cf | CurrentYearDuration | -31000000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YearDuration | 140000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYearDuration | 36020000 | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | Prior1YearDuration | － | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | CurrentYearDuration | 1560000 | JPY |
| Repayments of installment payables fin cf | Prior1YearDuration | -18067000 | JPY |
| Repayments of installment payables fin cf | CurrentYearDuration | － | JPY |
| Repayments of finance lease obligations fin cf | Prior1YearDuration | -40893000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYearDuration | -30601000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -74579000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -74891000 | JPY |
| Other net fin cf | Prior1YearDuration | -37000 | JPY |
| Other net fin cf | CurrentYearDuration | － | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -368673000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -610324000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 95873000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 648067000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1086848000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1182721000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1182721000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 1830789000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 2 | |
| Accumulated depreciation ppe by group | Prior1YearInstant | -5290079000 | JPY |
| Accumulated depreciation ppe by group | CurrentYearInstant | -5554022000 | JPY |
| Directors compensations sga | Prior1YearDuration | 155253000 | JPY |
| Directors compensations sga | CurrentYearDuration | 145194000 | JPY |
| Salaries and allowances sga | Prior1YearDuration | 634993000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 615765000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 22851000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 23877000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 96047000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 97534000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E36714-000MedicineBusinessReportableSegmentMember | 8986009000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E36714-000NursingCareBusinessReportableSegmentMember | 3444157000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E36714-000NurturingBusinessReportableSegmentMember | 8874431000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 21304599000 | JPY |
| Revenues from external customers | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 944792000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 22249391000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 22249391000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E36714-000MedicineBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E36714-000NursingCareBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E36714-000NurturingBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 29373000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |